Search
Sarepta Therapeutics Inc
SRPTAdd to Watchlist
19.380USD
-1.430-6.87%
Market hours 09/23, 11:27（ET）
2.05BMarket Cap
31.10P/E TTM
About Sarepta Therapeutics Inc Company
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The Company has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Sarepta Therapeutics Inc Profile
Ticker SymbolSRPT
Company nameSarepta Therapeutics Inc
IPO dateJun 04, 1997
CEOIngram (Douglas S)
Number of employees1372
Security typeOrdinary Share
Fiscal year-endJun 04
Address215 First Street
CityCAMBRIDGE
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02142
Phone16172744000
Websitehttps://www.sarepta.com/
Ticker SymbolSRPT
IPO dateJun 04, 1997
CEOIngram (Douglas S)
Company Executives of Sarepta Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.23M
+0.52%
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.23M
+0.52%
Dr. Michael E. Severino, M.D.
Dr. Michael E. Severino, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
756.10K
--
Dr. Michael E. Severino, M.D.
Dr. Michael E. Severino, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
756.10K
--
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
-138.12%
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
48.41K
+34.86%
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
48.41K
+34.86%
Dr. Hans Wigzell, M.D., Ph.D.
Dr. Hans Wigzell, M.D., Ph.D.
Independent Director
Independent Director
42.10K
+40.09%
Dr. Hans Wigzell, M.D., Ph.D.
Dr. Hans Wigzell, M.D., Ph.D.
Independent Director
Independent Director
42.10K
+40.09%
Mr. Dallan Murray
Mr. Dallan Murray
Executive Vice President, Chief Customer Officer
Executive Vice President, Chief Customer Officer
38.20K
+44.57%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.23M
+0.52%
Mr. Richard J. (Rick) Barry
Mr. Richard J. (Rick) Barry
Independent Director
Independent Director
3.23M
+0.52%
Dr. Michael E. Severino, M.D.
Dr. Michael E. Severino, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
756.10K
--
Dr. Michael E. Severino, M.D.
Dr. Michael E. Severino, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
756.10K
--
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Mr. Douglas S. (Doug) Ingram, Esq., J.D.
Chief Executive Officer
Chief Executive Officer
390.31K
-138.12%
Dr. Claude Nicaise, M.D.
Dr. Claude Nicaise, M.D.
Independent Director
Independent Director
48.41K
+34.86%
FAQs
Who are the top five shareholders of Sarepta Therapeutics Inc?
The top five shareholders of Sarepta Therapeutics Inc are: Mr. Richard J. (Rick) Barry
How many institutions hold shares of Sarepta Therapeutics Inc (SRPT)?
As of 2026Q1, 1037 institutions hold shares of Sarepta Therapeutics Inc, with a combined market value of approximately 95.57M, accounting for 90.53% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -25265811.00.
What is the biggest source of revenue for Sarepta Therapeutics Inc?
In 2026Q1, the PMO Products business generated the highest revenue for Sarepta Therapeutics Inc, amounting to 230.56M and accounting for 57.46% of total revenue.